Eli Lilly and Company $LLY Shares Bought by Global Retirement Partners LLC

Global Retirement Partners LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 33.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 23,979 shares of the company’s stock after buying an additional 5,956 shares during the quarter. Global Retirement Partners LLC’s holdings in Eli Lilly and Company were worth $25,770,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of LLY. Mach 1 Financial Group LLC lifted its holdings in shares of Eli Lilly and Company by 171.2% in the fourth quarter. Mach 1 Financial Group LLC now owns 3,792 shares of the company’s stock valued at $4,075,000 after purchasing an additional 2,394 shares in the last quarter. Fortis Group Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 13.2% in the fourth quarter. Fortis Group Advisors LLC now owns 3,545 shares of the company’s stock valued at $3,683,000 after purchasing an additional 414 shares in the last quarter. Callahan Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 2.5% in the fourth quarter. Callahan Advisors LLC now owns 19,162 shares of the company’s stock valued at $20,593,000 after purchasing an additional 468 shares in the last quarter. Harmony Asset Management LLC lifted its holdings in shares of Eli Lilly and Company by 0.6% in the fourth quarter. Harmony Asset Management LLC now owns 9,661 shares of the company’s stock valued at $10,383,000 after purchasing an additional 59 shares in the last quarter. Finally, Legacy Financial Group Inc. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $295,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.5%

NYSE LLY opened at $1,016.05 on Thursday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $956.85 billion, a PE ratio of 36.09, a price-to-earnings-growth ratio of 1.11 and a beta of 0.48. The firm’s fifty day simple moving average is $940.69 and its 200-day simple moving average is $1,002.07.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the prior year, the business posted $3.34 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on LLY. Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Wells Fargo & Company increased their target price on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. The Goldman Sachs Group increased their target price on Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the company a “buy” rating in a report on Friday, May 1st. Finally, Argus increased their target price on Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a report on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,218.33.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Late-stage Phase 3 data for Lilly’s experimental weight-loss drug retatrutide showed dramatic results, with patients losing about 28% of body weight on average over 80 weeks, strengthening the case for a future approval and expanding Lilly’s obesity pipeline. Article Title
• Positive Sentiment: CNBC reported that retatrutide cleared a crucial obesity trial, moving Lilly one step closer to seeking approval for what could become another major blockbuster in the GLP-1/obesity market. Article Title
• Positive Sentiment: The New York Times highlighted the same retatrutide results, reinforcing investor optimism that Lilly can keep dominating the rapidly growing weight-loss-drug category. Article Title
• Positive Sentiment: Reuters said lower-priced Lilly and Novo Nordisk obesity pills are drawing patients away from compounded alternatives, suggesting branded products are gaining share and supporting longer-term commercial demand. Article Title
• Neutral Sentiment: Lilly also completed an $8.9 billion debt offering and acquired Engage Biologics for up to $202 million, moves that support pipeline expansion but may also modestly increase financing and integration costs. Article Title
• Neutral Sentiment: Reports on Lilly’s TuneLab AI partnership and broader R&D recognition are supportive of the company’s innovation story, but they are less likely to move the stock than the obesity-trial headlines. Article Title
• Negative Sentiment: Separately, Lilly disclosed a lawsuit alleging more than $200 million in Trulicity rebate fraud, which is a legal overhang, though it is not the main driver of today’s sentiment. Article Title

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.